INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known	
Application Number	10/584,640
Filing Date	1/10/2005
First Named Inventor	Bock, Susan
Group Art Unit	1656
Examiner Name	Unassigned

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate
	A1	5,204,253	04/20/1993	Sanford et al.	435	459	
	A2	5,420,252	05/30/1995	Kato et al.	530	393	
	A3	5,618,713	04/08/1997	Zettlemeissl et al.	435	226	
	A4	5,700,663	12/23/1997	Zettlemeissl et al.	435	69.6	
	A5	5,843,705	12/01/1998	DiTullio et al.	800	7	
	A6	5,876,433	03/02/1999	Lunn et al.	623	001	
	A7	6,878,813	04/12/2005	Bock et al.	530	393	
	A8	2006/0259987	11/16/2006	Bock et al.			

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No
	A9	EP 0 568 833 A1	11/10/1993	Eisai Co. Ltd.	
	A10	EP 0 809 999 A1	12/03/1997	Ethicon Inc.	
	A11	WO 90/09737	07/09/1990	Blood Research Center	
	A12	WO 91/00291	01/10/1991	Akzo	
	A13	WO 95/05853	03/02/1995	Carson et al.	
	A14	WO 95/19799	07/27/1995	McCabe	
	A15	WO 99/58098	11/18/1999	Bock et al.	
	A16	WO 03/101398 A2	12/11/2003	University of Utah Research Foundation	

NON-PATENT DOCUMENTS

Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)
	A17	Ali, M., Mazur, W., Kleinman, N., Rodgers, G., Abukhalil, J., French, B., and Rainzer, A. (1996) Inhibition of coronary restenosis by antithrombin III in atherosclerotic swine Coronary Artery Dis. 7:851-61.
	A18	Anderson, H., Kirkeeide, R., Krishnaswami, A., Weigelt, L., Revana, M., Weisman, H., and Willerson, J. (1994) Cyclic flow variations after coronary angioplasty in humans: clinical and angiographic characteristics and elimination with 7E3 monoclonal antiplatelet antibody J. Am. Coll. Cardiol. 23:1031-7.
	A19	Arocas, V., Turk, B., Bock, S., Olson, S., and Bjork, I. (2000) The region of antithrombin interacting with full-length heparin chains outside the high-affinity pentasaccharide sequence extends to Lys136 but not to Lys139 Biochemistry 39:8512-8.
	A20	Backovic and Gettins, "Insight into residues critical for antithrombin function from an expanded database of sequences that includes frog, turtle and ostrich antithrombins." J. Proteome Res. 2002 1:367-373.
	A21	Bayston, T., Tripodi, A., Mannucci, P., Thompson, E., Ireland, H., Fitches, A., Hananeia, L., Olds, R., and Lane, D. (1999) Familial overexpression of beta antithrombin caused by an Asn135Thr substitution Blood 93:4242-7.

Examiner Signature:	Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/584,640
	Filing Date	1/10/2005
	First Named Inventor	Bock, Susan
	Group Art Unit	1656
	Examiner Name	Unassigned

	A22	Begovac, P., Thomson, R., Fisher, J., Hughson, A., and Gallhagen, A. (2003) Improvements in GORE-TEX vascular graft performance by Carmeda bioactive surface heparin immobilization Eur. J. Vasc. and Endovasc. Surg. 25:432-7.
	A23	Belzar KJ, Zhou A, Carrell RW, Gettins PG, Huntington JA. Helix D elongation and allosteric activation of antithrombin. J Biol Chem. 2002 Mar 8;277(10):8551-8. Epub 2001 Dec 10.
	A24	Bick et al. "Antithrombin III patterns in disseminated intravascular coagulation." Am. J. Clin. Pathol. 1980 73(4):577-83.
	A25	Bjork, I., Ylinenjarvi, K., Olson, S.T., Hermentin, P., Conradt, H.S., Zettlmeissl, G. (1992) Decreased affinity of recombinant antithrombin for heparin due to increased glycosylation Biochem J 286(Pt 3):793-800.
	A26	Blauhut et al. "Substitution of antithrombin III in shock and DIC: a randomized study." Thromb. Res. 1985 39(1):81-9.
	A27	Blezer R, Fouache B, Willems GM, Lindhout T. (1997) Activation of blood coagulation at heparin-coated surfaces. J Biomed Mater Res. 37:108-13.
	A28	Bock et al. "Cloning and expression of the cDNA for human antithrombin III." Nucleic Acids Res. 1982 10(24):8113-25.
	A29	Bock et al., "Cleaved and inactivated antithrombin III in bronchoalveolar lavage (BAL) samples from acute respiratory distress (ARDS) and at-risk for ARDS patents," Proteases/Antiproteases, seminar, Amer. J. Respir. Crit. Care Med., 2001, A63. (Poster Abstract)
	A30	Brennan et al. "Physiological variant of antithrombin-III lacks carbohydrate sidechain at Asn 135." FEBS Lett. 1987 219(2):431-6.
	A31	Buller and Cate, "Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate." Am. J. Med. 1989 87(3B):44S-48S.
	A32	Carlson et al. "Comparison of the behavior in vivo of two molecular forms of antithrombin III." Biochem. J. 1985 225:557-64.
	A33	Carlson, T., and Atencio, A. (1982) Isolation and partial characterization of two distinct types of antithrombin III from rabbit Thromb Res. 27:23-34.
	A34	Carlson, T., Atencio, A., and Simon, T. (1984) In vivo behavior of radioiodinated rabbit antithrombin III. Demonstration of a noncirculating vascular compartment J Clin Invest. 74:191-9
	A35	Carlson, T., Atencio, A., and Simon, T. (1985) Comparison of the behavior in vivo of two molecular forms of antithrombin III Biochem. J. 225:557-64.
	A36	Carlson, T., Simon, T., and Atencio, A. (1985) In vivo behavior of human radioiodinated antithrombin III: distribution among three physiologic pools Blood 66:13-9.
	A37	Carrell and Owen, "Plakalbumin, alpha 1-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis." Nature. 1985 317(6039):730-2.
	A38	Cohen, J., Tenenbaum, N., Sarfati, I., Tyras, D., Graver, L., Weinstein, G., and Wise, L. (1992) In vivo inactivation of antithrombin III is promoted by heparin during cardiopulmonary bypass J. Invest. Surg. 5:45-9.
	A39	Cunningham et al. "Development of an elastase-resistant antithrombin through mutagenesis at P4." Blood. 1995 86(10 Supp.):375A.
	A40	Cunningham et al. "Impact of mutations at the P4 and P5 position on the reation of antithrombin with thrombin and elastase." Thromb. Res. 1997 88(2):171-81.
	A41	Damus and Wallace, "Immunologic measurement of antithrombin III-heparin cofactor and alpha2 macroglobulin in disseminated intravascular coagulation and hepatic failure coagulopathy." Thromb Res. 1975 6(1):27-38.

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/584,640
	Filing Date	1/10/2005
	First Named Inventor	Bock, Susan
	Group Art Unit	1656
	Examiner Name	Unassigned

	A42	deAgostini, A., Watkins, S., Slayter, H., Youssoufian, H., and Rosenberg, R. (1990) Localization of anticoagulantly active heparan sulfate proteoglycans iin vascular endothelium: Antithrombin binding on cultured endothelial cells and perfused rat aorta J. Cell Biol. 111:1293-1304.
	A43	Delsharnmar et al. "Abnormal proteolysis (DIC)--successful treatment with antithrombin III concentrate and a concentrate containing F XIII and native von Willebrand factor." J. Intern. Med. 1989 225(1):21-7.
	A44	Desai, U., Swanson, R., Bock, S., Bjork, I., and Olson, S. (2000) Role of arginine 129 in heparin binding and activation of antithrombin J Biol Chem 275:18967-84.
	A45	Devine, C., Hons, B., and McCollum, C. (2001) Heparin-bonded dacron or polytetrafluoroethylene for femoropipliteal bypass grafting: a multicenter trial J. Vasc. Surg. 33:533-9.
	A46	Dewerchin, M., Hérault, J.-P., Wallays, G., Petitou, M., Schaeffer, P., Millet, L., Weitz, J., Moons, L., Collen, D., Carmeliet, P., and Herbert, J.-M. (2003) Life-threatening thrombosis in mice with targeted Arg48-to-Cys mutation of the heparin-binding domain of antithrombin Circ. Res. 93.
	A47	Dickneite and Paques, "Reduction of mortality with antithrombin III in septicemic rats: a study of Klebsiella pneumoniae induced sepsis." Thromb Haemost. 1993 69(2):98-102.
	A48	Dunzendorfer, S., Kaneider, N., Rabensteiner, A., Meierhofer, C., Reinisch, C., Römisch, J., and Wiedermann, C. (2001) Cell-surface heparan sulfate proteoglycanmediatedregulation of human neutrophil migration by the serpin antithrombin III Blood 97:1079-85.
	A49	Emerson et al. "Efficacy of antithrombin III supplemtation in animal models of fulminant Eschericia coli endotoxemia or bacteremia." Am. J. Med. 1989 87:27S-33S.
	A50	Emerson et al. "Protection against disseminated intravascular coagulation and death by antithrombin-III in the Escherichia coli endotoxemic rat." Circ Shock. 1987 21(1):1-13.
	A51	Ersdal-Badju, E., Lu, A., Peng, X., Picard, V., Zendehrouh, P., Turk, B., Björk, I., Olson, S., and Bock, S. (1995) Elimination of glycosylation heterogeneity affecting heparin affinity of recombinant human antithrombin III by expression of a beta-like variant in baculovirus-infected insect cells. Biochem. J. 310:323-30.
	A52	Fourrier et al. "Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation." Chest. 1993 104(3):882-8.
	A53	Franzen et al. "Structural studies on the carbohydrate portion of human antithrombin III." J. Biol. Chem. 1980 255(11):5090-3.
	A54	Frebelius et al. "Thrombin inhibition by antithrombin III on the subendothelium is explained by the isoform AT-beta." Thromb. Vasc. Biol. 1996 16:1292-7.
	A55	Garone, L., Edmunds, T., Hanson, E., Bernasconi, R., Huntington, J.A., Meagher, J.L., Fan, B., Gettins, P.G. (1996) Antithrombin-heparin affinity reduced by fucosylation of carbohydrate at asparagine 155 Biochemistry 35(27):8881-9.
	A56	Goldsmith, H., and Turrito, V. (1986) Rheological aspects of thrombosis and haemostasis: Basic principles and applications Thromb. Haemost. 55:415-35.
	A57	Goldstein, D. (2003) Worldwide experience with the MicroMed DeBakey ventricular assist device as a bridge to transplantation Circulation 108 (suppl. II), 272-7.
	A58	Grip, L., Blomback, M., Egberg, N., Olsson, A., Svane, B., and Velander, M. (1997) Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double-blind pilot study Eur. Heart J. 18:443-9.

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/584,640
	Filing Date	1/10/2005
	First Named Inventor	Bock, Susan
	Group Art Unit	1656
	Examiner Name	Unassigned

	A59	HajMohammadi, S., Enjyoji, K., Princivalle, M., Christi, P., Lech, M., Beeler, D., Rayburn, H., Schwartz, J., Barzegar, S., Agostini, A. d., Post, M., Rosenberg, R., and Shworak, N. (2003) Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis J. Clin. Invest. 111:989-99.
	A60	Hamilton et al. "Production of complex human glycoproteins in yeast." Science. 2003 301:1244-6.
	A61	Harker, L., Kelly, A., and Hanson, S. (1991) Experimental arterial thrombosis in nonhuman primates Circulation 83 (Suppl. IV), 41-55.
	A62	Hedin et al. "Antithrombin III inhibits thrombin-induced proliferation in human arterial smooth muscle cells." Arterioscler Thromb. 1994 14(2):254-60.
	A63	Hellgren et al. "Antithrombin III concentrate as adjuvant in DIC treatment. A pilot study in 9 severely ill patients." Thromb Res. 1984 35(4):459-66.
	A64	Hellgren et al. "Blood coagulation and fibrinolytic factors and their inhibitors in critically ill patients." Intensive Care Med. 1984 10(1):23-8.
	A65	Herbert, J., Herault, J., Bernat, A., vanAmsterdam, R., Vogel, G., Lormeau, J., Petitou, M., and Meuleman, D. (1996) Biochemical and pharmacological properties of SANORG 32701. Comparison with the 'synthetic pentasaccharide' (SR 90107/ORG 31540) and standard heparin Circulation Res. 79:590-600.
	A66	Hoffmann, J., Vollmar, B., Römisch, J., Inthorn, D., Schildberg, F., and Menger, M. (2002) Antithrombin effects on endotoxin-induced microcirculatory disorders are mediated mainly by its interaction with microvascular endothelium Crit. Care Med. 30, 218-25.
	A67	Ishiguro, K. et al. "Complete antithrombin deficiency in mice results in embryonic lethality." J. Clin. Invest. 2000 106(7):873-878.
	A68	Jairajpuri et al. "Antithrombin III phenylalanines 122 and 121 contribute to its high affinity for heparin and its conformational activation." J. Biol. Chem. 2003 278:15941-50.
	A69	Jairajpuri et al. "Elimination of P1 arginine-393 interaction with underlying glutamic acid-255 partially activates antithrombin III for thrombin inhibition but not factor Xa inhibition." J. Biol. Chem. 2002 277:24460-5.
	A70	Jin, L., Abrahams, J., Skinner, R., Petitou, M., Pike, R., and Carrell, R. (1997) The anticoagulant activation of antithrombin by heparin Proc Natl Acad Sci USA 94:14683-8.
	A71	Jochum et al. "Effect of human granulocytic elastase on isolated human antithrombin III." Hoppe Seylers Z Physiol Chem. 1981 362(2):103-12.
	A72	Jochum, "Influence of high-dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation." Semin Hematol. 1995 32(4 Suppl 2):19-32.
	A73	Jordan et al. "Heparin promotes the inactivation of antithrombin by neutrophil elastase." Science. 1987 237(4816):777-9.
	A74	Jordan, "Antithrombin in vertebrate species: conservation of the heparin-dependent anticoagulant mechanism." Arch. Biochem. Biophys. 1983 227(2):587-95.
	A75	Kato et al. "Recombinant antithrombin III mutations with enhanced antithrombin activity without heparin." 69th Scientific Sessions, Abstract 4336, 1996 94:8 Supp., p. I-741.
	A76	Kelly, A., Marzec, U., Krupski, W., Bass, A., Cadroy, Y., Hanson, S., and Harker, L. (1991) Hirudin interruption of heparin-resistant arterial thrombosis formation in baboons Blood 77:1006-12.
	A77	Kocsis, J., Llanos, G., and Holmer, E. (2000) Heparin-coated stents J. of Long-Term Effects of Medical Implants 10:19-45.

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/584,640
	Filing Date	1/10/2005
	First Named Inventor	Bock, Susan
	Group Art Unit	1656
	Examiner Name	Unassigned

	A78	Kurachi et al. "Inhibition of bovine factor IXa and factor Xabeta by antithrombin III." Biochemistry. 1976 15(2):373-7.
	A79	Lammle et al. "Plasma prekallikrein, factor XII, antithrombin III, C1(-)-inhibitor and alpha 2-macroglobulin in critically ill patients with suspected disseminated intravascular coagulation (DIC)." Am. J. Clin. Pathol. 1984 82(4):396-404.
	A80	Larm, O., Larsson, R., and Olsson, P. (1983) A new nonthrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue Biomater. Med. Dev. Artif. Organs 11:161-3.
	A81	Lawrence, D., Ginsburg, D., Day, D., Berkenpas, M., Verhamme, I., Kvassman, J., and Shore, J. (1995) Serpin-protease complexes are trapped as stable acyl-enzyme intermediates J Biol Chem 270:25309-12.
	A82	Lawson et al. "Complex-dependent inhibition of factor VIIa by antithrombin III and heparin." J. Biol. Chem. 1993 268(2):767-70.
	A83	Lott, F., Nelson, A., and Toombs, C. (1998) Effects of recombinant human megakaryocyte growth and development factor (rHuMGDF) on platelet production, platelet aggregation and thrombosis J. of Thrombosis and Thrombolysis 5:15-23.
	A84	Malek, A., Alper, S., and Izumo, S. (1999) Hemodynamic shear stress and its role in atherosclerosis JAMA 282:2035-42.
	A85	Mammen et al. "Human antithrombin concentrates and experimental disseminated intravascular coagulation." Semin. Thromb. Hemost. 1985 11(4):373-83.
	A86	Mant et al. "Haemorrhagic complications of heparin therapy." Lancet. 1977 1(8022):1133-5.
	A87	Marcum et al. "Microvascular heparin-like species with anticoagulant activity." Am. J. Physiol. 1983 245(5 Pt 1):H725-33.
	A88	Meagher, J., Beechem, J., Olson, S., and Gettins, P. (1996) Role of arginine 132 and lysine 133 in heparin binding to and activation of antithrombin J Biol Chem 271:29353-8.
	A89	Minnema et al. "Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli." Blood. 2000 95(4):1117-23.
	A90	Mizuochi et al. "Structural studies of the carbohydrate moiety of human antithrombin III." Arch. Biochem. Biophys. 1980 203(1):458-65.
	A91	Myszka, D., He, X., Dembo, M., Morton, T., and Goldstein, B. (1998) Extending the range of rate constants available for BIACORE: Interpreing mass transport influenced binding data Biophysical J. 75:583-94.
	A92	Nakajima et al., "Mapping the extended substrate binding site of cathepsin G and human leukocyte elastase," J. Biol. Chem. 1979 254:4027.
	A93	Nuijens et al. "Plasma elastase alpha 1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis." J. Lab. Clin. Med. 1992 119(2):159-68.
	A94	O'Reilley et al. "Antiangiogenic activity of the cleaved conformation of the serpin antithrombin." Science. 1999 285(5435):1926-8.
	A95	Oelschläger, C., Römisch, J., Staubitz, A., Stauss, H., Leithäuser, B., Tillmanns, H., and Hölschermann, H. (2002) Antithrombin III inhibits nuclear factor kappa B activation in human monocytes and vascular endothelial cells Blood 99, 4015-20.
	A96	Olson et al. "Identification of critical molecular interactions mediating heparin activation of antithrombin. Implications for the design of improved heparin anticoagulants." Trends Cardiovasc. Med. 2002 12:198-205.

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/584,640
	Filing Date	1/10/2005
	First Named Inventor	Bock, Susan
	Group Art Unit	1656
	Examiner Name	Unassigned

	A97	Olson et al. "Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement." J. Biol. Chem. 1992 267(18):12528-38.
	A98	Olson, S., Swanson, R., Raub-Segall, E., Bedsted, T., Sadri, M., Petitou, M., Herault, J., Herbert, J., and Bjork, I. (2004) Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin Thrombosis and Haemostasis 92(5):929-39.
	A99	Olson, S.T., Frances-Chmura, A.M., Swanson, R., Bjork, I., Zettlmeissl, G. (1997) Effect of individual carbohydrate chains of recombinant antithrombin on heparin affinity and on the generation of glycoforms differing in heparin affinity Arch Biochem Biophys 341(2):212-21.
	A100	Ostrovsky et al. "Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion." Circulation. 1997 96(7):2302-10.
	A101	Owen et al." P1 variant antithrombins Glasgow (393 Arg to His) and Pescara (393 Arg to Pro) have increased heparin affinity and are resistant to catalytic cleavage by elastase. Implications for the heparin activation mechanism." FEBS Lett. 1991 280(2):216-20.
	A102	Petersen et al. (1979) The Physiological Inhibitors of Coagulation and Fibrinolysis, Elsevier/North Holland Biomedical Press. 1979 pp. 43-54.
	A103	Peterson and Blackburn, "Isolation and characterization of an antithrombin III variant with reduced carbohydrate content and enhanced heparin binding." J. Biol. Chem. 1985 260(1):610-5.
	A104	Picard and Bock, "Rapid and efficient one-tube PCR-based mutagenesis method." Methods in Mol. Biol. Vol. 67, PCR Cloning Protocols. From moluclar cloning to genetic engineering. B.A. White Humana Press, Totowa, NJ, 1996, 183-8.
	A105	Picard et al. "A rapid and efficient one-tube PCR-based mutagenesis technique using Pfu DNA polymerase." Nucleic Acid Res. 1994 22(13):2587-91.
	A106	Picard, V., Ersdal-Badju, E., and Bock, S. (1995) Partial glycosylation of antithrombin III asparagine-135 is caused by the serine in the third position of its N-glycosylation consensus sequence and is responsible for production of beta-antithrombin III isoform with enhanced heparin affinity Biochemistry 34:8433-40.
	A107	Rao et al. "Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa." Blood. 1993 81(10):2600-7.
	A108	Rosenberg and Damus, "The purification and mechanism of action of human antithrombin-heparin cofactor." J. Biol. Chem. 1973 248(18):6490-505.
	A109	Rosenberg, "Chemistry of the hemostatic mechanism and its relationship to the action of heparin." Fed. Proc. 1977 36(1):10-8.
	A110	Rothenburger, M., Wilhelm, M., Hammel, D., Schmidt, C., Tjan, T., Bocker, D., Scheld, H., and Schmid, C. (2002) Treatment of thrombus formation associated with theMicroMed DeBakey VAD using recombinant tissue plasminogen activator Circulation 106 [suppl I], I-189-192.
	A111	Rubsamen, K., Hornberger, W., and Kirchengast, M. (1995) Inhibition of arterial thrombus formation in two canine models: comparison of ancrod, a fibrinogen-depleting agent, the thrombin-inhibitor r-hirudin, and the glycoprotein 11b/IIIa-receptor antagonist Ro 43-8857 Thromb Haemost. 74:1353-60.
	A112	Ruf and Mueller, "Tissue factor in cancer angiogenesis and metastasis." Curr. Opin. Hematol. 1996 3(5):379-84.

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/584,640
	Filing Date	1/10/2005
	First Named Inventor	Bock, Susan
	Group Art Unit	1656
	Examiner Name	Unassigned

	A113	Schreuder, H., deBoer, B., Dijkema, R., Mulders, J., Theunissen, H., Grootenhuis, P., and Hol, W. (1994) The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions Struct Biol 1:48-54.
	A114	Seitz et al. "Participation and interactions of neutrophil elastase in haemostatic disorders of patients with severe infections." Eur. J. Haematol. 1987 38(3):231-40.
	A115	Skinner, R., Abrahams, J., Whisstock, J., Lesk, A., Carrell, R., and Wardell, M. (1997) The 2.6A structure of antithrombin indicates a conformational change at the heparin binding site J Mol Biol 266:601-9.
	A116	Stephens et al. "Site directed mutagenesis of the reactive center (serine 394) of antithrombin III." J. Biol. Chem. 1988 263(31):15849-52.
	A117	Tani et al. "Thrombin enhances lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis." Am. J. Respir. Cell Mol. Biol. 1991 5(1):34-40.
	A118	Tejada, M.L. and Deeley, R.G. "Cloning of an avian antithrombin: developmental and hormonal regulation of expression." Thromb. Haemost. 1995 73(4):654-661.
	A119	Turk, B., Brieditis, I., Bock, S., Olson, S., and Bjork, I. (1997) The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the affinity of the inhibitor by affecting the heparin-induced conformational change Biochemistry 36:6682-91.
	A120	Uchiba et al. "Antithrombin III (AT III) prevents LPS-induced pulmonary vascular injury: novel biological activity of AT III." Semin. Thromb. Hemost. 1997 23(6):583-90.
	A121	Valentin, J., Vieu, S., Bertolino, F., Faure, P., and John, G. (1997) Differential involvement of serontonin 2A/C and thromboxane A2/Prostanoid receptors in high- vs. low-shear rate arterial thrombosis in rabbits J. Pharmacology and Experimental Therapeutics 280:761-9.
	A122	van Boven and Lane, "Antithrombin and its inherited deficiency states." Semin. Hematol. 1997 34(3):188-204.
	A123	Varga et al. "Infectious entry pathway of adenovirus type 2." J. Virol. 1991 65(11):6061-70.
	A124	Vinazzer, Clin. Appl. Thrombosis/Hemostasis. 1995 1:62-5.
	A125	Warren et al. "High-dose antithrombin III in severe sepsis: a randomized controlled trial." JAMA. 2001 286(15):1869-78.
	A126	Weitz, J. (2003) Heparan sulfate: Antithrombotic or not? J. Clin. Invest. 111:952-4.
	A127	Wilczynska, M., Fa, M., Ohlsson, P.-I., and Ny, T. (1995) The inhibition mechanism of serpins. Evidence that the mobile reactive center loop is cleaved in the native protease-inhibitor complex J Biol Chem 270:29652-5.
	A128	Witmer, M., and Hatton, M. (1991) Antithrombin III-beta associates more readily than antithrombin III-alpha with uninjured and de-endothelialized aortic wall in vitro and in vivo Arteriosclerosis and Thrombosis 11:530-9.
	A129	Wolff et al. "Direct gene transfer into mouse muscle in vivo." Science. 1990 247(4949 Pt 1):1465-8.
	A130	Wong, P., Crain, E., O, O. N., Watson, C., and Racanelli, A. (1996) Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis Thromb Res. 83:117-26.
	A131	Zendehrouh, Ph.D. Dissertation, "Novel proteinase inhibitors for use in treatment of sepsis." Temple Univ. School of Medicine, publically available at the Univeristy of Michigan dissertation archive in 1999.

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

IDS PROSECUTION DOCUMENT COVER SHEET

ATTENTION:
The documents listed in the table below are being provided in an **Information Disclosure Statement** for **Matsui et al., Application Serial No. 10/584,640** (*see* **APPENDIX A**).

These documents are copies of the prosecution documents from another application and are not being submitted as a separate or original filing.

Please do not record or file these documents in the Application identified therein or charge any fees associated therewith.

Initials	Attorney Docket Number	Application Number	Inventor / Applicant	Application Filing Date	Document	Date of Document
	21101.0021P1	PCT/US03/17506	Bock et al.	6/2/2003	Notification of Transmittal of the International Search Report or the Declaration	3/17/2005

IDS PROSECUTION DOCUMENT COVER SHEET

ATTENTION:

The documents listed in the table below are being provided in an **Information Disclosure Statement** for **Matsui et al., Application Serial No. 10/584,640** (*see* **APPENDIX A**).

These documents are copies of the prosecution documents from another application and are not being submitted as a separate or original filing.

Please do not record or file these documents in the Application identified therein or charge any fees associated therewith.

Initials	Attorney Docket Number	Application Number	Inventor / Applicant	Application Filing Date	Document	Date of Document
	21101.0004U3	10/014,658	Bock et al.	12/11/2001	Certificate of Correction - Post Issue Communication	3/13/2007
	21101.0004U3	10/014,658	Bock et al.	12/11/2001	Request for Certificate of Correction	12/28/2006
	21101.0004U3	10/014,658	Bock et al.	12/11/2001	Certificate of Correction - Post Issue Communication	10/17/2006
	21101.0004U3	10/014,658	Bock et al.	12/11/2001	Request for Certificate of Correction	10/3/2006
	21101.0004U3	10/014,658	Bock et al.	12/11/2001	Notice of Allowance and Fees Due (PTOL-85)	11/8/2004
	21101.0004U3	10/014,658	Bock et al.	12/11/2001	Examiner Interview Summary Record (PTOL - 413)	8/26/2004
	21101.0004U3	10/014,658	Bock et al.	12/11/2001	Amendment - After Non-Final Rejection	8/11/2004
	21101.0004U3	10/014,658	Bock et al.	12/11/2001	Examiner Interview Summary Record (PTOL - 413)	7/27/2004
	21101.0004U3	10/014,658	Bock et al.	12/11/2001	Non-Final Rejection	4/8/2004
	21101.0004U3	10/014,658	Bock et al.	12/11/2001	Preliminary Amendment	8/19/2003
	21101.0004U3	10/014,658	Bock et al.	12/11/2001	Preliminary Amendment	10/11/2002
	21101.0004U3	10/014,658	Bock et al.	12/11/2001	Preliminary Amendment	12/11/2001
	21101.0004U3	10/014,658	Bock et al.	12/11/2001	Preliminary Amendment	12/11/2001

IDS PROSECUTION DOCUMENT COVER SHEET

ATTENTION:
The documents listed in the table below are being provided in an **Information Disclosure Statement** for **Matsui et al., Application Serial No. 10/584,640** (*see* **APPENDIX A**).

These documents are copies of the prosecution documents from another application and are not being submitted as a separate or original filing.

Please do not record or file these documents in the Application identified therein or charge any fees associated therewith.

Initials	Attorney Docket Number	Application Number	Inventor / Applicant	Application Filing Date	Document	Date of Document
	21101.0054P1	PCT/US05/00843	Bock et al.	1/10/2005	International Search Report	12/27/2005
	21101.0054P1	PCT/US05/00843	Bock et al.	1/10/2005	Written Opinion	12/27/2005
	21101.0054P1	PCT/US05/00843	Bock et al.	1/10/2005	International Preliminary Report on Patentability	7/10/2006

IDS PROSECUTION DOCUMENT COVER SHEET

ATTENTION:
The documents listed in the table below are being provided in an **Information Disclosure Statement** for **Matsui et al., Application Serial No. 10/584,640** (*see* **APPENDIX A**).

These documents are copies of the prosecution documents from another application and are not being submitted as a separate or original filing.

Please do not record or file these documents in the Application identified therein or charge any fees associated therewith.

Initials	Attorney Docket Number	Application Number	Inventor / Applicant	Application Filing Date	Document	Date of Document
	21101.0054EP1	05705482.7	Bock et al.	1/10/2005	Amended Claims	11/20/2006
	21101.0054EP1	05705482.7	Bock et al.	1/10/2005	Supplementary European Search Report	8/1/2008

IDS PROSECUTION DOCUMENT COVER SHEET

ATTENTION:

The documents listed in the table below are being provided in an **Information Disclosure Statement** for **Matsui et al., Application Serial No. 10/584,640** (*see* **APPENDIX A**).

These documents are copies of the prosecution documents from another application and are not being submitted as a separate or original filing.

Please do not record or file these documents in the Application identified therein or charge any fees associated therewith.

Initials	Attorney Docket Number	Application Number	Inventor / Applicant	Application Filing Date	Document	Date of Document
	21101.0004U2	09/305,588	Bock et al.	5/5/1999	Notice of Abandonment	6/4/2002
	21101.0004U2	09/305,588	Bock et al.	5/5/1999	Interview Summary	10/26/2001
	21101.0004U2	09/305,588	Bock et al.	5/5/1999	Final Rejection	6/12/2001
	21101.0004U2	09/305,588	Bock et al.	5/5/1999	Response to Amendment	4/5/2001
	21101.0004U2	09/305,588	Bock et al.	5/5/1999	Amendment - After Non-Final Rejection	12/5/2000
	21101.0004U2	09/305,588	Bock et al.	5/5/1999	Response to Restriction Requirement	11/6/2000
	21101.0004U2	09/305,588	Bock et al.	5/5/1999	Restriction Requirement	10/4/2000

IDS PROSECUTION DOCUMENT COVER SHEET

ATTENTION:
The documents listed in the table below are being provided in an **Information Disclosure Statement** for **Matsui et al., Application Serial No. 10/584,640** (*see* **APPENDIX A**).

These documents are copies of the prosecution documents from another application and are not being submitted as a separate or original filing.

Please do not record or file these documents in the Application identified therein or charge any fees associated therewith.

Initials	Attorney Docket Number	Application Number	Inventor / Applicant	Application Filing Date	Document	Date of Document
	21101.0004AU1	41868/99	Bock et al.	5/12/1999	Examination Report	3/19/2002

IDS PROSECUTION DOCUMENT COVER SHEET

ATTENTION:
The documents listed in the table below are being provided in an **Information Disclosure Statement** for **Matsui et al., Application Serial No. 10/584,640** (*see* **APPENDIX A**).

These documents are copies of the prosecution documents from another application and are not being submitted as a separate or original filing.

Please do not record or file these documents in the Application identified therein or charge any fees associated therewith.

Initials	Attorney Docket Number	Application Number	Inventor / Applicant	Application Filing Date	Document	Date of Document
	21101.0021EP1	03756385.5	Bock et al.	6/2/2003	Examination Report	9/1/2008
	21101.0021EP1	03756385.5	Bock et al.	6/2/2003	Supplementary Parital European Search Report	10/10/2007
	21101.0021EP1	03756385.5	Bock et al.	6/2/2003	Supplementary Parital European Search Report	7/24/2007
	21101.0021EP1	03756385.5	Bock et al.	6/2/2003	Amended Claims	2/18/2005

IDS PROSECUTION DOCUMENT COVER SHEET

ATTENTION:
The documents listed in the table below are being provided in an **Information Disclosure Statement** for **Matsui et al., Application Serial No. 10/584,640** (*see* **APPENDIX A**).

These documents are copies of the prosecution documents from another application and are not being submitted as a separate or original filing.

Please do not record or file these documents in the Application identified therein or charge any fees associated therewith.

Initials	Attorney Docket Number	Application Number	Inventor / Applicant	Application Filing Date	Document	Date of Document
	21101.0021U2	10/516,662	Bock et al.	3/13/2006	Notice of Allowance	9/8/2008
	21101.0021U2	10/516,662	Bock et al.	3/13/2006	Notice of Allowability	9/8/2008
	21101.0021U2	10/516,662	Bock et al.	3/13/2006	Response to Notice of Non-Compliant Amendment	7/10/2008
	21101.0021U2	10/516,662	Bock et al.	3/13/2006	Notice of Non-Compliant Amendment	6/10/2008
	21101.0021U2	10/516,662	Bock et al.	3/13/2006	Response to Amendment	5/9/2008
	21101.0021U2	10/516,662	Bock et al.	3/13/2006	Non-Final Rejection	11/9/2007
	21101.0021U2	10/516,662	Bock et al.	3/13/2006	Response to Election / Restriction Filed	9/17/2007
	21101.0021U2	10/516,662	Bock et al.	3/13/2006	Requirement for Restriction/Election	7/17/2007
	21101.0021U2	10/516,662	Bock et al.	3/13/2006	Preliminary Amendment	3/13/2006
	21101.0021U2	10/516,662	Bock et al.	3/13/2006	Preliminary Amendment	11/30/2004

IDS PROSECUTION DOCUMENT COVER SHEET

ATTENTION:
The documents listed in the table below are being provided in an **Information Disclosure Statement** for **Matsui et al., Application Serial No. 10/584,640** (*see* **APPENDIX A**).

These documents are copies of the prosecution documents from another application and are not being submitted as a separate or original filing.

Please do not record or file these documents in the Application identified therein or charge any fees associated therewith.

Initials	Attorney Docket Number	Application Number	Inventor / Applicant	Application Filing Date	Document	Date of Document
	21101.0004P1	PCT/US99/10549	Bock et al.	5/12/1999	International Search Report	4/6/2000

IDS PROSECUTION DOCUMENT COVER SHEET

ATTENTION:
The documents listed in the table below are being provided in an **Information Disclosure Statement** for **Matsui et al., Application Serial No. 10/584,640** (*see* **APPENDIX A**).

These documents are copies of the prosecution documents from another application and are not being submitted as a separate or original filing.

Please do not record or file these documents in the Application identified therein or charge any fees associated therewith.

Initials	Attorney Docket Number	Application Number	Inventor / Applicant	Application Filing Date	Document	Date of Document
	21101.0004EP1	99925618.3	Bock et al.	5/12/1999	Examination Report	7/24/2008
	21101.0004EP1	99925618.3	Bock et al.	5/12/1999	Response to Examination Report	8/21/2006
	21101.0004EP1	99925618.3	Bock et al.	5/12/1999	Examination Report	2/10/2006
	21101.0004EP1	99925618.3	Bock et al.	5/12/1999	Supplementary Partial European Search Report	7/4/2003